Completed PHASE1 INTERVENTIONAL 4-arm NCT03709927

4-way Crossover QT Evaluation in Healthy Subjects

A Phase 1, Randomized, Blinded, Placebo and Moxifloxacin Controlled, 4-Period Crossover, Study Evaluating the Effect of ZTI-01 on 12-Lead Electrocardiogram Parameters in Healthy Adult Subject

Sponsor: Nabriva Therapeutics AG

Conditions Cardiac Repolarization in Healthy Subjects

Interventions Moxifloxacin 400mg Placebo IV ZTI-01

Updated 5 times since 2018 Last updated: Mar 5, 2019 Started: Jan 11, 2018 Primary completion: Apr 12, 2018 Completion: Aug 21, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Cardiac Repolarization in Healthy Subjects, this trial is completed. The trial is conducted by Nabriva Therapeutics AG and has accumulated 5 data snapshots since 2018. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Apr 2019 — Jan 2021 [monthly]

Completed PHASE1
Nov 2018 — Apr 2019 [monthly]

Completed PHASE1

First recorded

Jan 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nabriva Therapeutics AG

Data source: Nabriva Therapeutics AG

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Baltimore, United States